21:22 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Anergis' AllerT meets in Phase IIb for birch pollen allergy

In September, Anergis S.A. (Epalinges, Switzerland) reported top-line data from the Phase IIb ATIBAR trial in 421 patients with birch pollen allergy showing that 50 μg doses of subcutaneous AllerT met the primary endpoint of...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

AllerT: Phase IIb data

Data from 196 patients in the follow-up Phase IIb AN005T trial showed that 50 and 100 ug doses of subcutaneous AllerT each improved mean RSMS scores during the second birch pollen season (2014) following treatment,...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AllerT: Phase II started

Anergis began a double-blind, placebo-controlled, dose-ranging, Canadian Phase II trial to evaluate 10, 25 and 50 µg subcutaneous AllerT given 5 times over 2 months in about 180 patients with birch tree pollen allergy. Anergis...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Pollen for Anergis

By topping off its series B financing, Anergis S.A. hopes to make its short-term birch pollen allergy vaccine into a long-term winner. The additional CHF14.5 million ($15 million) in funding brings the series B total...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

AllerT: Completed clinical trial enrollment

Anergis completed enrollment of 196 patients with moderate to severe birch pollen allergy in a double-blind, placebo-controlled, European observational study evaluating subcutaneous AllerT for up to 3 years. All patients participated in the double-blind, placebo-controlled,...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

AllerT: Additional Phase IIb data

Additional data from the double-blind, European Phase IIb AN004T trial in 240 patients with moderate to severe birch pollen allergy showed that 50 and 100 µg doses of subcutaneous AllerT each led to a 20-fold...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

AllerT: Phase IIb data

The double-blind, European Phase IIb AN004T trial in 240 patients with moderate to severe birch pollen allergy showed that 50 µg subcutaneous AllerT met the primary endpoint of reducing combined RSMS scores during the 2013...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

AllerT: Phase IIb started

Anergis began the double-blind, placebo-controlled, European Phase IIb AN004T trial to evaluate 2 dose levels of subcutaneous AllerT given on days 1, 7, 14, 28 and 56 in about 300 patients with moderate to severe...
07:00 , Apr 4, 2011 |  BioCentury  |  Finance

Nothing to Sneeze at

Nothing to sneeze at Classic allergy desensitization techniques using a whole allergen require three to five years of treatment, during which patients often experience mild allergic reactions. Anergis S.A. believes its desensitization technology can work...
00:48 , Mar 29, 2011 |  BC Extra  |  Financial News

Anergis raises $19.6 million in series A

Allergy company Anergis S.A. (Epalinges, Switzerland) raised CHF18 million ($19.6 million) in a series A round co-led by Vinci Capital - Renaissance PME; BioMedInvest; and Sunstone. Esperante BV; Initiative Capital Romandie; and private investors also...